- Oral presentation
- Open Access
Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV-positive patients on HAART
© O’Doherty et al; licensee BioMed Central Ltd. 2010
- Published: 04 November 2010
- Public Health
- Infectious Disease
- Patient Sample
- Longitudinal Analysis
- Significant Excess
How HIV reservoirs are maintained on HAART remains unclear. Ongoing replication may contribute to reservoir maintenance and may occur at a low level that is not easy to detect. In the absence of ongoing replication, unintegrated HIV DNA should be lost over time; thus, monitoring total and integrated DNA may address this question.
We developed and validated a sensitive and precise assay to measure HIV integration. Total and integrated HIV DNA were then measured in a cross-sectional series of patients on HAART and in two patients longitudinally. The ratios of total over integrated were then calculated to determine the extent of unintegrated HIV DNA present in patient samples. The errors in the ratios were calculated to determine the lowest level of excess unintegrated HIV DNA that we could confidently detect.
All HIV-positive patients off HAART have an excess of unintegrated HIV DNA. Surprisingly, we found a statistically significant excess of unintegrated HIV DNA in three of seven well-suppressed patients in the cross-sectional study. We detected an excess of unintegrated HIV DNA sporadically in both of the patients that we evaluated longitudinally, with two of eight positive time points in one patient and four of 10 in the other. Notably, for most time points in the longitudinal analysis, the levels of total and integrated HIV DNA were not significantly different.
Our data suggest that unintegrated HIV DNA can be detected sporadically in patients on HAART. Further work is required to determine the meaning of an excess of unintegrated HIV DNA. We speculate that an excess of unintegrated HIV DNA may correlate with a burst of ongoing replication. If so, these methods could aid in the evaluation of therapies that aim to intensify HAART or flush out viral reservoirs in patients on HAART.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.